Caroline J Davidge-Pitts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6890194/publications.pdf

Version: 2024-02-01

840585 610775 27 755 11 citations h-index papers

g-index 27 27 27 910 docs citations times ranked citing authors all docs

24

#	Article	IF	CITATIONS
1	Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3914-3923.	1.8	184
2	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5 . 5	129
3	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	1.4	116
4	Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3904-3913.	1.8	87
5	Transgender Health in Endocrinology: Current Status of Endocrinology Fellowship Programs and Practicing Clinicians. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1286-1290.	1.8	51
6	Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine, 2018, 62, 721-728.	1.1	34
7	Proper Care of Transgender and Gender Diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective*. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 305-308.	1.8	24
8	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	2.0	21
9	Letter to the Editor: "Progesterone Is Important for Transgender Women's Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3127-3128.	1.8	15
10	Transfeminine Hormone Therapy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 341-355.	1.2	14
11	A community-based study of demographics, medical and psychiatric conditions, and gender dysphoria/incongruence treatment in transgender/gender diverse individuals. Biology of Sex Differences, 2020, 11, 55.	1.8	13
12	The Effect of Gender-Affirming Hormone Therapy on Serum Creatinine in Transgender Individuals. Endocrine Practice, 2022, 28, 52-57.	1.1	12
13	Pituitary Tumor Surgery: Comparison of Endoscopic and Microscopic Techniques at a Single Center. Mayo Clinic Proceedings, 2021, 96, 2043-2057.	1.4	12
14	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
15	An Approach to Nonsuppressed Testosterone in Transgender Women Receiving Gender-Affirming Feminizing Hormonal Therapy. Journal of the Endocrine Society, 2021, 5, bvab068.	0.1	6
16	Characteristics of Transgender Women Referred to Women's Heart Clinic. American Journal of Preventive Cardiology, 2021, 7, 100223.	1.3	6
17	Dermatologic disorders in transgender patients: A retrospective cohort of 442 patients. Journal of the American Academy of Dermatology, 2020, 83, 1516-1518.	0.6	5
18	A Comprehensive Study of Spindle Cell Oncocytoma of the Pituitary Gland: Series of 6 Cases and Meta-Analysis of 85 Cases. World Neurosurgery, 2021, 149, e197-e216.	0.7	4

#	Article	IF	CITATIONS
19	Mimics of Erdheim–Chester disease. British Journal of Haematology, 2021, , .	1.2	3
20	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	1.9	3
21	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	2.8	3
22	Breaking Down Barriers to Reproductive Care for Transgender People. AACE Clinical Case Reports, 2022, 8, 96-98.	0.4	2
23	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. Blood, 2018, 132, 1112-1112.	0.6	1
24	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	0.6	1
25	Response to Letter to the Editor from Malone: "Proper Care of Transgender and Gender Diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3295-e3296.	1.8	0
26	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7049-7049.	0.8	0
27	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7050-7050.	0.8	0